The Heads of Medicines Agencies (HMA) is a network of the heads of the National Competent Authorities (NCA) whose organisations are responsible for the regulation of medicinal products for human and veterinary use in the European Economic Area.
The HMA co-operates with the European Medicines Agency (EMA) and the European Commission in the operation of the European medicines regulatory network and it is a unique model for cooperation and worksharing on statutory as well as voluntary regulatory activities.
- addresses key strategic issues for the network, such as the exchange of information, IT developments and sharing of best practices
- focuses on the development, co-ordination and consistency of the European medicines regulatory system
- ensures the most effective and efficient use of resources across the network. This includes developing and overseeing arrangements for work-sharing
- co-ordinates the mutual recognition (MRP) and decentralised procedures (DCP).
Member agencies support the network by providing high-quality professional and scientific resources to all areas of medicines regulation including centralised, MRP, DCP and national procedures.
ABOUT HMA | RECENTLY PUBLISHED
The United Kingdom submitted on 29 March 2017 the notification of its...
CTFG Key documents list
HMA, EMA and the European Commission working against COVID-19
Launch of public consultation on joint network strategy to 2025
28 May, Cisco Webex, Zagreb (Croatia) - 100th HMA Meeting HMA II Stakeholders...
Periodic Safety Update Reporting (PSUR) - Synchronisation and Work-sharing
HMA leaflet 'Protecting and Promoting Public and Animal Health in Europe | pdf
Updated July 2019